Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.7K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

804
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
804
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

6.0K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
6.0K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

379
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
379
Inhibitors of Bacterial Protein Synthesis01:25

Inhibitors of Bacterial Protein Synthesis

99
Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
99
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

978
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
978

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Obesity in young adults: The differentiated impact of LEP, LEPR, and FTO gene variants.

Genetics and molecular biology·2026
Same author

Genotyping of Mycobacterium leprae in humans and six-banded armadillos suggests lack of inter-species transmission in Rio Grande do Norte, northeast Brazil.

Acta tropica·2026
Same author

Intestinal microbiota profile and inflammation in patients undergoing hemodialysis: a comparison between the Southern and Southeastern regions of Brazil.

Jornal brasileiro de nefrologia·2026
Same author

Neutrophil extracellular traps promote macrophage activation through Toll-like receptor engagement and PKA and NF-kB signaling pathways.

Cell communication and signaling : CCS·2026
Same author

Amitriptyline for neuropathic pain in patients with leprosy: a bicenter randomized controlled trial.

Pain·2026
Same author

Vascular Immune Crosstalk in COVID-19: RAAS Biomarker Signature Linking Angiotensin II to Respiratory Compromise and Soluble ACE2 to IL-13 and FGF, Revealing Therapeutic Targets.

International journal of molecular sciences·2026

Related Experiment Video

Updated: Apr 26, 2026

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

8.1K

Statins increase rifampin mycobactericidal effect.

Lívia Silva Lobato1, Patrícia Sammarco Rosa2, Jessica da Silva Ferreira1

  • 1Laboratório de Microbiologia Celular, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Rio de Janeiro, Brazil.

Antimicrobial Agents and Chemotherapy
|July 23, 2014
PubMed
Summary

Statins show promise in fighting mycobacterial infections like leprosy and tuberculosis. Combining atorvastatin with rifampin significantly reduced mycobacteria viability and lesions in mice.

More Related Videos

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

7.4K
Metabolic Profiling to Determine Bactericidal or Bacteriostatic Effects of New Natural Products using Isothermal Microcalorimetry
07:28

Metabolic Profiling to Determine Bactericidal or Bacteriostatic Effects of New Natural Products using Isothermal Microcalorimetry

Published on: October 29, 2020

9.9K

Related Experiment Videos

Last Updated: Apr 26, 2026

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

8.1K
A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

7.4K
Metabolic Profiling to Determine Bactericidal or Bacteriostatic Effects of New Natural Products using Isothermal Microcalorimetry
07:28

Metabolic Profiling to Determine Bactericidal or Bacteriostatic Effects of New Natural Products using Isothermal Microcalorimetry

Published on: October 29, 2020

9.9K

Area of Science:

  • Microbiology
  • Immunology
  • Pharmacology

Background:

  • Antimicrobial resistance in Mycobacterium leprae and Mycobacterium tuberculosis is a growing concern.
  • New drugs are urgently needed to combat leprosy and extensively drug-resistant tuberculosis (XDR-TB).
  • Mycobacterium leprae utilizes host cells to promote its survival and replication.

Purpose of the Study:

  • To investigate the efficacy of statins against intracellular mycobacteria.
  • To evaluate atorvastatin's effect on Mycobacterium leprae infection in a mouse model.

Main Methods:

  • Incubation of macrophages with statins and mycobacteria.
  • Administration of atorvastatin to BALB/c mice infected with M. leprae.
  • Assessment of intracellular mycobacterial viability and inflammatory markers.

Main Results:

  • Both statins tested reduced intracellular mycobacteria viability.
  • Atorvastatin demonstrated the most significant inhibitory effect, especially when combined with rifampin.
  • Atorvastatin controlled M. leprae infection and reduced footpad inflammation in mice, correlating with serum cholesterol levels.

Conclusions:

  • Statins enhance macrophage bactericidal activity against Mycobacterium bovis, M. leprae, and M. tuberculosis.
  • Combining statins with current multidrug therapy may reduce mycobacterial viability and lesions in patients.
  • Further epidemiological studies are required to confirm these findings in human populations.